Media headlines about Ardelyx (NASDAQ:ARDX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ardelyx earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.2801315018142 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Ardelyx (ARDX) opened at $5.90 on Tuesday. Ardelyx has a 1 year low of $4.05 and a 1 year high of $15.40.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.10. During the same quarter in the previous year, the company earned ($0.65) earnings per share. research analysts predict that Ardelyx will post -2.01 earnings per share for the current fiscal year.

A number of brokerages have issued reports on ARDX. BidaskClub raised shares of Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $12.00 price objective on shares of Ardelyx in a research report on Tuesday, November 21st. Leerink Swann reissued an “outperform” rating and set a $13.00 price objective on shares of Ardelyx in a research report on Tuesday, October 17th. Wedbush reissued an “outperform” rating and set a $12.00 price objective (down from $13.00) on shares of Ardelyx in a research report on Tuesday, November 28th. Finally, Ladenburg Thalmann Financial Services reduced their price objective on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. Ardelyx currently has a consensus rating of “Buy” and an average target price of $12.64.

In other news, COO Reginald Seeto sold 10,008 shares of the company’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $5.20, for a total value of $52,041.60. The transaction was disclosed in a filing with the SEC, which is available through this link. 15.47% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Ardelyx (ARDX) Share Price” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at

About Ardelyx

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with's FREE daily email newsletter.